Originally developed for type 2 diabetes, these therapies are now helping thousands achieve effective, doctor-supervised weight reduction
Dosing Comparison# Retatrutide Dosing# Based on Phase 2 clinical trial protocols (investigational only): Starting dose : 0.5 mg weekly subcutaneous injection Escalation : Gradual increase over 12-24 weeks to target dose (up to 12 mg) Target doses tested : 1, 4, 8, and 12 mg weekly Escalation rationale : Extended 24-week escalation for higher doses reduces GI side effects compared to faster 12-week escalation No commercial formulation exists
ONE ID
The only lawful route of access is participation in an approved clinical trial
The 5/5 vial gives equal parts of each, which is the ratio most closely matched by the published 1:1 blend protocols
Unlike traditional clinic-based models, MEDVis digital-first approach ensures convenient access to licensed physicians , online evaluations, and direct medication delivery all from the comfort of home